Premium
Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa
Author(s) -
TasAygar Gamze,
Gonul Muzeyyen,
Ozcan Ibrahim,
Ayli Mehmet Deniz,
ErtoyBaydar Dilek
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14205
Subject(s) - hidradenitis suppurativa , secukinumab , medicine , amyloidosis , dermatology , aa amyloidosis , quality of life (healthcare) , psoriasis , disease , pathology , familial mediterranean fever , psoriatic arthritis , nursing
Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory disease of follicular epithelium; many comorbidities occur that disrupt the quality of life of patients. Amyloidosis is one of them. We present a case with systemic amyloidosis secondary to HS and responding positively to secukinumab therapy. Secukinumab may also be an important option for amyloidosis findings in HS patients.